As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

Zealand Pharma achieved notable organizational growth in 2024 with a 30% increase in the number of employees compared to 2023 ...

No. 2 / 2025Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant clinical ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

At this time, I would like to welcome everyone to the Karyopharm Therapeutics fourth quarter and full year 2024 financial results conference call. There will be a question-and-answer session to follow ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its ...